Photo: Eisai website

Ei­sai fol­lows fam­i­ly ties with name for new­ly ap­proved Alzheimer's drug Leqem­bi

The road to ap­proval for Alzheimer’s drug Leqem­bi be­gan more than a decade ago when Ei­sai and Bio­gen col­lab­o­rat­ed on a first tri­al for what was then called BAN2401. The amy­loid be­ta-di­rect­ed ther­a­py went through years of study be­fore lecanemab be­came its rec­om­mend­ed in­ter­na­tion­al non-pro­pri­etary (INN) name in Sep­tem­ber 2020.

Last week, the FDA green­lit the in­fused drug and it be­came of­fi­cial­ly rec­og­nized by its pro­pri­etary brand Leqem­bi.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.